Zoetis (ZTS) said Tuesday that it has updated the US label for Librela following its submission of a supplement to the US Food and Drug Administration based on post-approval experiences with the veterinary drug.
The company said it remains confident in the safety and effectiveness of the treatment for the pain associated with osteoarthritis in dogs.
The company said that out of 25 million doses, no adverse event has been reported at a rate higher than rare, representing less than 10 occurrences per 10,000 treated dogs.
Shares of the company were down more than 1% in Tuesday's premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。